RU2734924C2 - Способ вакцинации против аутоантигена у пациента-человека - Google Patents

Способ вакцинации против аутоантигена у пациента-человека Download PDF

Info

Publication number
RU2734924C2
RU2734924C2 RU2018120009A RU2018120009A RU2734924C2 RU 2734924 C2 RU2734924 C2 RU 2734924C2 RU 2018120009 A RU2018120009 A RU 2018120009A RU 2018120009 A RU2018120009 A RU 2018120009A RU 2734924 C2 RU2734924 C2 RU 2734924C2
Authority
RU
Russia
Prior art keywords
autoantigen
booster
mimotope
immune response
dose
Prior art date
Application number
RU2018120009A
Other languages
English (en)
Russian (ru)
Other versions
RU2018120009A (ru
RU2018120009A3 (cg-RX-API-DMAC10.html
Inventor
Гергана ГАЛАБОВА
Сабине ШМИДХУБЕР
Ахим ШНЕБЕРГЕР
Арне ФОН БОНИН
Дориан ВИНТЕР
Яна ЦИММЕРМАНН
Original Assignee
Аффирис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аффирис Аг filed Critical Аффирис Аг
Publication of RU2018120009A publication Critical patent/RU2018120009A/ru
Publication of RU2018120009A3 publication Critical patent/RU2018120009A3/ru
Application granted granted Critical
Publication of RU2734924C2 publication Critical patent/RU2734924C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
RU2018120009A 2015-11-03 2016-11-02 Способ вакцинации против аутоантигена у пациента-человека RU2734924C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15192794 2015-11-03
EP15192794.4 2015-11-03
PCT/EP2016/076372 WO2017076873A1 (en) 2015-11-03 2016-11-02 Method for vaccination against a self-antigen in a human patient

Publications (3)

Publication Number Publication Date
RU2018120009A RU2018120009A (ru) 2019-12-04
RU2018120009A3 RU2018120009A3 (cg-RX-API-DMAC10.html) 2020-04-23
RU2734924C2 true RU2734924C2 (ru) 2020-10-26

Family

ID=54396782

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018120009A RU2734924C2 (ru) 2015-11-03 2016-11-02 Способ вакцинации против аутоантигена у пациента-человека

Country Status (10)

Country Link
US (1) US12290553B2 (cg-RX-API-DMAC10.html)
EP (1) EP3370761A1 (cg-RX-API-DMAC10.html)
JP (2) JP7378931B2 (cg-RX-API-DMAC10.html)
KR (1) KR102857456B1 (cg-RX-API-DMAC10.html)
CN (1) CN108472344A (cg-RX-API-DMAC10.html)
AU (1) AU2016348610B2 (cg-RX-API-DMAC10.html)
BR (1) BR112018008697A2 (cg-RX-API-DMAC10.html)
CA (1) CA3003943A1 (cg-RX-API-DMAC10.html)
RU (1) RU2734924C2 (cg-RX-API-DMAC10.html)
WO (1) WO2017076873A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3003943A1 (en) * 2015-11-03 2017-05-11 Affiris Ag Method for vaccination against a self-antigen in a human patient
AR111760A1 (es) * 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
JP2021525074A (ja) * 2018-05-22 2021-09-24 ザ・ガバナーズ・オブ・ザ・ユニバーシティー・オブ・アルバータ 構造に基づくアミロイド疾患ワクチン及び抗原のための無害な構造化足場
JP7898188B2 (ja) 2020-08-04 2026-07-31 エイシー イミューン ソシエテ アノニム 免疫原性化合物
KR102527616B1 (ko) 2021-03-18 2023-05-02 정성욱 항체 관련 정보를 제공하는 방법 및 디바이스
IL314865A (en) 2022-02-09 2024-10-01 Ac Immune Sa Anti-alpha-synuclein therapeutic vaccines
WO2025172592A1 (en) 2024-02-15 2025-08-21 Ac Immune Sa Alpha synuclein therapeutic vaccine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101077416A (zh) 2002-10-23 2007-11-28 葛兰素史密丝克莱恩生物有限公司 抗疟疾的疫苗接种方法
AT413945B (de) 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT506535B1 (de) 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
AT508569A1 (de) 2009-07-23 2011-02-15 Affiris Ag Pharmaceutical compound
AT508638B1 (de) 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
KR101660578B1 (ko) 2009-09-03 2016-09-27 화이자 백신스 엘엘씨 Ｐｃｓｋ９ 백신
JP5814933B2 (ja) 2009-12-15 2015-11-17 ノバルティス アーゲー 免疫増強化合物の均質な懸濁物およびその使用
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
PL3110439T3 (pl) 2014-02-28 2019-09-30 Affiris Ag Szczepionki PCSK9
CA3003943A1 (en) * 2015-11-03 2017-05-11 Affiris Ag Method for vaccination against a self-antigen in a human patient

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Affis AG: First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development, 31.07.2014. *
Affis AG: First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development, 31.07.2014. Mandler, M., Valera, E., Rockenstein, E. et al. Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mol Neurodegeneration 10, 10 (2015). Похоленко Я. А., Влияние бустерной иммунизации фрагмента Е2 ВКЧС на иммунный ответ, индуцированный маркированной ДНК-вакциной против КЧС.Biopolymers & Cell, Том 28, Изд.2, 2012, стр.134-140. *
Mandler, M., Valera, E., Rockenstein, E. et al. Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mol Neurodegeneration 10, 10 (2015). *
Похоленко Я. А., Влияние бустерной иммунизации фрагмента Е2 ВКЧС на иммунный ответ, индуцированный маркированной ДНК-вакциной против КЧС.Biopolymers & Cell, Том 28, Изд.2, 2012, стр.134-140. *

Also Published As

Publication number Publication date
JP7378931B2 (ja) 2023-11-14
JP2018532782A (ja) 2018-11-08
JP2023175708A (ja) 2023-12-12
WO2017076873A1 (en) 2017-05-11
AU2016348610A1 (en) 2018-05-10
JP7628333B2 (ja) 2025-02-10
EP3370761A1 (en) 2018-09-12
RU2018120009A (ru) 2019-12-04
RU2018120009A3 (cg-RX-API-DMAC10.html) 2020-04-23
BR112018008697A2 (en) 2018-10-30
AU2016348610B2 (en) 2023-08-31
CN108472344A (zh) 2018-08-31
KR20180079406A (ko) 2018-07-10
US12290553B2 (en) 2025-05-06
KR102857456B1 (ko) 2025-09-08
CA3003943A1 (en) 2017-05-11
US20190091306A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
JP7628333B2 (ja) ヒト患者における自己抗原に対するワクチン接種法
AU2005216100B2 (en) Methods and compositions comprising supramolecular constructs
US10253070B2 (en) Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
US20110092436A1 (en) Compounds for treating symptoms associated with parkinson's disease
JP5559789B2 (ja) アルツハイマー病の処置のための免疫治療組成物
KR20120004994A (ko) 치료적 이용 방법
US20150093431A1 (en) Compositions
JP2009519915A (ja) 治療ワクチン
JP2023536497A (ja) 免疫原性化合物
Wang et al. Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1 (A246E) transgenic mouse model of Alzheimer's disease
DK2465533T3 (en) Methods and compositions comprising supramolecular constructs
EA048154B1 (ru) Иммуногенные соединения
US20220218806A1 (en) Peptides and conjugates for treatment of arthritis
HK40087814A (en) Immunogenic compounds
NZ744411A (en) Amyloid conjugate and uses and methods thereof
NZ744411B2 (en) Amyloid conjugate and uses and methods thereof

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20211230